Literature DB >> 1358556

Distribution of IL-2R and CD45Ro expression on CD4+ and CD8+ T-lymphocytes in the peripheral blood of patients with posterior uveitis.

E J Feron1, V L Calder, S L Lightman.   

Abstract

Different lines of evidence support a major role for activated T-lymphocytes in the pathogenesis of posterior uveitis. The initial site of activation of these autoreactive T-cells, either locally in the eye or in the peripheral immune compartment, is still unknown. This study was undertaken to investigate whether with currently available techniques, it is possible to detect alterations in the levels and subsets of activated T-cells in the peripheral blood of patients with posterior uveitis. For this reason, 3-colour immunofluorescent staining was performed to assess the distribution of IL-2 receptors (IL-2R) and the CD45RO-antigen on CD4+ and CD8+ subsets of peripheral blood lymphocytes (PBLs) from patients with posterior uveitis (n = 29). Only the subgroup of patients with posterior uveitis as part of a systemic immune-mediated disease (sarcoidosis, Behçet's disease) (n = 9) showed a significant increase in IL-2R expression on peripheral blood lymphocytes (p less than 0.005) when compared to normals (n = 12). This increased expression was reflected much more significantly in the CD4+ (p less than 0.0005) rather than in the CD8+ subset (p less than 0.05) of lymphocytes. In contrast, no significant increase in CD45RO expression on either subset of T lymphocytes was found in any subgroup of posterior uveitis in comparison with normals.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1358556     DOI: 10.3109/02713689208999528

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  6 in total

Review 1.  Immunomodulation of autoimmune responses with monoclonal antibodies and immunoadhesins: treatment of ocular inflammatory disease in the next millennium.

Authors:  A D Dick; J D Isaacs
Journal:  Br J Ophthalmol       Date:  1999-11       Impact factor: 4.638

Review 2.  Management of sight-threatening uveitis: new therapeutic options.

Authors:  Matthias D Becker; Justine R Smith; Regina Max; Christoph Fiehn
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  Experimental approaches to specific immunotherapies in autoimmune disease: future treatment of endogenous posterior uveitis?

Authors:  A D Dick
Journal:  Br J Ophthalmol       Date:  1995-01       Impact factor: 4.638

4.  Characterization of T cells and cytokines in the aqueous humour (AH) in patients with Fuchs' heterochromic cyclitis (FHC) and idiopathic anterior uveitis (IAU).

Authors:  M Muhaya; V Calder; H M Towler; B Shaer; M McLauchlan; S Lightman
Journal:  Clin Exp Immunol       Date:  1998-01       Impact factor: 4.330

5.  Peripheral CD25 positive T lymphocytes with biased T cell receptor Vbeta gene usage in autoimmune endogenous posterior uveitis.

Authors:  P J Tighe; J V Forrester; J Liversidge; H F Sewell
Journal:  Clin Mol Pathol       Date:  1995-02

6.  Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial.

Authors:  R B Nussenblatt; E Fortin; R Schiffman; L Rizzo; J Smith; P Van Veldhuisen; P Sran; A Yaffe; C K Goldman; T A Waldmann; S M Whitcup
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.